David Amsellem
Stock Analyst at Piper Sandler
(4.64)
# 178
Out of 4,944 analysts
149
Total ratings
59.32%
Success rate
20.97%
Average return
Main Sectors:
Stocks Rated by David Amsellem
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ABBV AbbVie | Assumes: Overweight | $231 | $200.75 | +15.07% | 1 | Aug 12, 2025 | |
| AMPH Amphastar Pharmaceuticals | Maintains: Neutral | $30 → $25 | $30.57 | -18.22% | 9 | Aug 8, 2025 | |
| CORT Corcept Therapeutics | Maintains: Overweight | $131 → $121 | $72.82 | +66.16% | 8 | Aug 1, 2025 | |
| NBIX Neurocrine Biosciences | Maintains: Overweight | $154 → $175 | $130.21 | +34.40% | 11 | Jul 31, 2025 | |
| AMGN Amgen | Reiterates: Overweight | $328 | $286.86 | +14.34% | 4 | Jun 27, 2025 | |
| BIIB Biogen | Reiterates: Neutral | $115 | $133.59 | -13.91% | 1 | Jun 12, 2025 | |
| OGN Organon & Co. | Maintains: Overweight | $24 → $18 | $9.31 | +93.44% | 6 | May 15, 2025 | |
| COLL Collegium Pharmaceutical | Reiterates: Neutral | $36 → $37 | $37.95 | -2.50% | 8 | May 9, 2025 | |
| JAZZ Jazz Pharmaceuticals | Reiterates: Overweight | $176 → $147 | $115.25 | +27.55% | 14 | May 7, 2025 | |
| BMY Bristol-Myers Squibb Company | Initiates: Overweight | $65 | $47.45 | +37.00% | 1 | Apr 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $3 → $4 | $7.31 | -45.24% | 5 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $16 → $13 | $22.83 | -43.06% | 5 | Mar 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $14 → $10 | $10.32 | -3.05% | 7 | Mar 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $23 → $30 | $16.88 | +77.73% | 10 | Jan 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $24 → $13 | $13.49 | -3.63% | 5 | Jan 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $9 → $11 | $9.12 | +20.61% | 4 | Nov 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $38 → $37 | $28.10 | +31.67% | 7 | Oct 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $68 | $88.87 | -23.48% | 1 | Oct 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $41 → $36 | $42.48 | -15.25% | 15 | Sep 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | $9 → $3 | $7.11 | -57.81% | 7 | Aug 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $42 | $25.06 | +67.58% | 10 | Jul 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $10 | $3.91 | +156.08% | 1 | Apr 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $20 → $21 | $1.07 | +1,862.62% | 3 | Feb 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $90 → $113 | $107.80 | +4.82% | 3 | Jan 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $72 → $42 | $36.21 | +15.99% | 3 | Oct 16, 2023 |
AbbVie
Aug 12, 2025
Assumes: Overweight
Price Target: $231
Current: $200.75
Upside: +15.07%
Amphastar Pharmaceuticals
Aug 8, 2025
Maintains: Neutral
Price Target: $30 → $25
Current: $30.57
Upside: -18.22%
Corcept Therapeutics
Aug 1, 2025
Maintains: Overweight
Price Target: $131 → $121
Current: $72.82
Upside: +66.16%
Neurocrine Biosciences
Jul 31, 2025
Maintains: Overweight
Price Target: $154 → $175
Current: $130.21
Upside: +34.40%
Amgen
Jun 27, 2025
Reiterates: Overweight
Price Target: $328
Current: $286.86
Upside: +14.34%
Biogen
Jun 12, 2025
Reiterates: Neutral
Price Target: $115
Current: $133.59
Upside: -13.91%
Organon & Co.
May 15, 2025
Maintains: Overweight
Price Target: $24 → $18
Current: $9.31
Upside: +93.44%
Collegium Pharmaceutical
May 9, 2025
Reiterates: Neutral
Price Target: $36 → $37
Current: $37.95
Upside: -2.50%
Jazz Pharmaceuticals
May 7, 2025
Reiterates: Overweight
Price Target: $176 → $147
Current: $115.25
Upside: +27.55%
Bristol-Myers Squibb Company
Apr 22, 2025
Initiates: Overweight
Price Target: $65
Current: $47.45
Upside: +37.00%
Mar 7, 2025
Reiterates: Neutral
Price Target: $3 → $4
Current: $7.31
Upside: -45.24%
Mar 6, 2025
Maintains: Overweight
Price Target: $16 → $13
Current: $22.83
Upside: -43.06%
Mar 5, 2025
Reiterates: Neutral
Price Target: $14 → $10
Current: $10.32
Upside: -3.05%
Jan 17, 2025
Maintains: Overweight
Price Target: $23 → $30
Current: $16.88
Upside: +77.73%
Jan 10, 2025
Maintains: Overweight
Price Target: $24 → $13
Current: $13.49
Upside: -3.63%
Nov 11, 2024
Maintains: Overweight
Price Target: $9 → $11
Current: $9.12
Upside: +20.61%
Oct 25, 2024
Reiterates: Overweight
Price Target: $38 → $37
Current: $28.10
Upside: +31.67%
Oct 11, 2024
Initiates: Overweight
Price Target: $68
Current: $88.87
Upside: -23.48%
Sep 11, 2024
Downgrades: Neutral
Price Target: $41 → $36
Current: $42.48
Upside: -15.25%
Aug 2, 2024
Downgrades: Underweight
Price Target: $9 → $3
Current: $7.11
Upside: -57.81%
Jul 3, 2024
Maintains: Overweight
Price Target: $42
Current: $25.06
Upside: +67.58%
Apr 11, 2024
Initiates: Overweight
Price Target: $10
Current: $3.91
Upside: +156.08%
Feb 16, 2024
Maintains: Overweight
Price Target: $20 → $21
Current: $1.07
Upside: +1,862.62%
Jan 16, 2024
Maintains: Overweight
Price Target: $90 → $113
Current: $107.80
Upside: +4.82%
Oct 16, 2023
Maintains: Overweight
Price Target: $72 → $42
Current: $36.21
Upside: +15.99%